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Abstract 
Rheumatoid arthritis (RA) is a chronic, systemic disorder characterised by inflammation of the joint synovial 
membrane associated with cytokine release resulted in progressive joint destruction. RA pathogenesis was 
thought to be initiated by bone resorption by osteoclasts, immune system activation and matrix 
metalloproteinase (MMP) production. Serum MMP-3 levels at the onset of disease is predictive of joint damage 
progression and thought to play an important role in joint destruction in RA. This study aimed to determine the 
presence of elevated serum MMP-3 in RA patients and to produce custom made patient derived anti-MMP-3 
antibody for diagnostic and prognostic purposes. We found significant increase of serum MMP-3 in RA patients 
participated in this study and able to produce anti-MMP-3 antibody from their serum. The success of MMP-3 
antibody production from RA patients in this study is novel and will be beneficial for future diagnostic and 
prognostic purposes for patients from similar geographical area. Currently none of the MMP-3 antibodies which 
are available commercially were produced in the Asian countries which raised questions about their specificity 
for the local use. 
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1. Introduction  
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory immune disorder that primarily affects the joints 
characterised with inflammation of synovial membranes and the release of inflammatory cytokines resulted in 
progressive joint destruction[1-4]. The progressive long term effect of joint destruction in RA leads to functional 
impairment, deterioration in quality of life, and severe disability [1, 3]. The aetiology of RA has not been clearly 
defined but previous investigators believe  that RA pathogenesis was initiated by bone resorption in the joint due 
to the action of osteoclasts [5] followed by immune system activation and matrix metalloproteinase (MMP) 
production.  Early features of rheumatoid joints is characterised by inflammatory cell infiltration associated with 
neovascularization and proliferation of synovial tissue. The areas of overgrown synovial tissue eventually 
became the major source of pro-inflammatory cytokines and MMPs production [4].   
MMPs are large group of zinc dependent proteases which have the ability to degrade component of extracellular 
matrix such as elastin, collagen, gelatine, and casein [6]. Serum levels of the MMPs including MMP-1, -3, -8, -9 
have been shown to be associated with disease activity in early RA [7, 8]. MMP-3 (stromelysin-1) is one of 
MMP family member that produced in the joints and it is a proteinase with wide range of substrate specificity. 
MMP-3 activity result in degradation of aggregan core protein, cartilage link protein, fibronectin, and collagen 
type III, IV, VII, IX, X and XI. MMP-3 can aggregate inflammation by activating pro-MMP-1, pro-MMP-7, 
pro-MMP-8, pro-MMP-9 and pro-MMP-13. MMP-3 is secreted by fibroblasts, chondrocytes and synovial cells 
and is considered the most important proteinase that responsible for cartilage degradation [4, 6]. MMP-3 levels 
has been shown to accurately predicted ongoing bonedestruction during Biological Agent treatment[2] and 
serum pro-MMP-3 levels at the onset of disease are also predictive of joint damage progression and thought to 
play an important role in joint destruction in RA [7, 8]. 
MMP-3 is locally produced in the inflamed joint and then released to the circulation [9]. Systemic MMP-3 
levels are a reflection of local synthesis and it was suggested that serum MMP-3 level is correlated with MMP-3 
produced by synovium and reflected the activity of RA [10, 11]. Previous investigators have shown that serum 
MMP-3 can be used as a systemic marker of local joint inflammation and/or destruction [12] and that serum 
concentration of MMP-3 in early stage of RA can be used as a marker for predicting the level of future 
progressive bone damage [4, 13]. Furthermore treating RA with the aim to target both normalisation of MMP-3 
as well as lowering the disease activity score to below 2.6 seems to yield better effects than treating RA with the 
aim of only either one of them [14]. 
As mentioned above previous studies have shown that serum MMP-3 level resembles the local joint synthesis 
and that arthritis progression is associated with increased level of serum MMP-3. The degree of increased level 
of serum MMP-3 can potentially be used as a reliable marker to determine the occurrence of disease activity and 
rate of future progressive joint destruction in RA and thus the prognosis of the disease [6, 15, 16]. The level of 
expression of serum MMP-3 can be easily measured from blood using venous puncture which is reasonably 
simple and non-invasive thus it is a favourable diagnostic tool.   
Caution is needed when using MMP-3 as an RA marker because of the presence of sex difference in the normal 
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range of MMP-3. The cut off value of serum immuno assay is twice as high for men as for women[17]. 
Furthermore serum MMP-3 level in non RA individuals is influenced by various treatments including 
glucocorticoids [18]. Glucocorticoid teatment in non RA individuals markedly increased the level of serum 
MMP-3 although the source of MMP-3 and the mechanism involved are unclear. [19-21]. In individuals with 
RA however, serum MMP-3 level were markedly increase regardless of being treated with/without 
glucocorticoids. Therefore if serum MMP-3 is to be used as a diagnostic tool for RA, the exclusion criteria for 
baseline MMP-3 in controls should include the past and current use of glucocorticoid therapy[18]. 
To characterize the presence of elevated serum MMP-3 in RA patients and to determine the occurrence of 
significant increase level of serum MMP-3 in RA patients in comparison to healthy individuals without RA the 
use of specific identification measures is pertinent. The MMP-3 specificity is crucial and the production of 
custom made antibody from RA sufferers with the same geographical location and environment is likely to be 
more accurate determinant factor and can minimise potential external factor variabilities. Due to the importance 
of finding an accurate M MP-3 marker to assist RA diagnosis and prognosis this study aimed to custom develop 
an MMP-3 antibody sourced from RA sufferer’s MMP-3 over production. If successful it is potentially can be 
used as a reliable marker to detect MMP-3 expression in RA patients from a specific geographical area. The 
antibody specificity will reduce or eliminate potential variabilities that could happen when using commercially 
available antibodies. Before the development of the anti-MMP-3 antibody the presence of significant elevation 
of serum MMP-3 in RA patients was firstly determined. The serum MMP-3 obtained from RA patients was 
characterized, isolated and then used to induce the production of anti-MMP-3 polyclonal in rabbits. 
2. Materials & Methods 
Five patients diagnosed with an established RA according to 1987 American College of Rheumatology (Arnett  
and his colleagues 1988) from Dr Soetomo Public Hospital, Surabaya, Indonesia (F; 40-55 yo) were recruited 
for this study. Controls were obtained from healthy individuals showed no sign of RA (M; 25-35 yo) and none 
of them were being treated with corticosteroids prior or at the time of their involvement in the study. Five ml 
blood were taken from each participants and centrifuged straight away at 3500 rpm for 20 minutes at room 
temperature to obtain the serum. The serum was stored in -80OC freezer until being used. Written and informed 
consent was obtained from all participants and the study was approved by the ethics committee at Dr Soetomo 
Public Hospital, Surabaya, Indonesia. 
2.1. Determination of MMP-3 level using indirect ELISA and SDS-PAGE methods 
All experiments were done in triplicates. Serum from RA patients and controls were thawed to room 
temperature. Using ELISA kit (Sigma-Aldrich, St. Louis, MO, USA) samples of 100 µL in volume were 
inserted in each microplate well and incubated in refrigerator at 4OC for 24 hr. They were then washed in 0,05% 
PBS-Tween for 3 minutes and repeated 3 times and blocked with 100 µL blocking buffer PBS-BSA 1% for 2 hr 
at room temperature, washed again with 0,05% PBS-Tween for 3 minutes and repeated 4 times. Primary 
antibody reaction was using 100 µL polyclonal anti human anti MMP-3 (Sigma-Aldrich) diluted 1:40 in 
blocking buffer and incubated for 2 hr at room temperature. After washing with 0,05% PBS-Tween (PBS-T) for 
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3 minutes and repeated 4 times 100 µL secondary antibody (IgG Biotin Labelled) was applied at the dilution of 
1:2500 in PBS-T and incubated at room temperature for 2hr. After washing with PBS-T for 3 minutes and 
repeated 3 times 100 µL SA-HRP substrate was added in each well and incubated for 30 min at room 
temperature in the dark. Once the colour of the controls turned yellow the reaction was stopped by adding 100µl 
1M HCL (Stop Reaction). The reading was done twice using ELISA reader at 450 nm wavelength. Negative 
controls were treated exactly the same without adding the antigen (sera RA patient or control). 
SDS-PAGE was used to determine the molecular weight of protein bands in the samples including MMP-3. 
Briefly 35 µL isolate serum protein were fed into each of the wells of SDS-PAGE gel next to a molecular 
weight marker and electrophoresed for 1.5 h at 130 V and 30 mA. The gel were then stained withcoomassie blue 
and put on a shaker for 30 min, destained repeatedly until the solution was cleared and the blue protein bands 
can be observed clearly. The possible presence of MMP-3 can be identified based on the molecular weight 
marker of the band by Western blot technique using MMP3 monoclonal antibody (Sigma-Aldrich, St. Louis, 
MO, USA) 
2.2. To determine the specificity of MMP-3 using  Western Blotting methods 
Western blot method was used to determine whether the protein that has a similar size with MMP-3 observed in 
SDS-PAGE gel was actually MMP-3.  
The protein in SDS-PAGE gel were transfered to Nitrocellulose (NC) membraneand blocked with 3% BSA in 
20 mM Tris-NaCl pH 7,5 and 150 mM NaCl for 1 hr. It was then incubated in Tris-Cl buffer  containing 1% 
BSA with monoclonalanti-MMP-3 as the primary antibody overnight (Sigma-Aldrich, St. Louis, MO, USA). 
The membrane was then washed twice in Tris-Cl buffer containing 0,05% Tween 20 for 10 min. The membrane 
was then incubated in secondary antibody anti human anti IgG alkaline phosphatase conjugated at 1:2500 
dilution (Sigma-Aldrich, St. Louis, MO, USA) for 1 hour, It was then washed again twice and stained with 
Western bluesubstrate to reveal the MMP-3 bands.  
For collecting Human MMP3 from the sera using unstained Native PAGE, gel was then cut along the confirmed 
MMP-3 band by Western blot. Each piece was inserted in the dialysis bag containing 1-2 ml of 0.05M 
phosphate buffer and electroeluted overnight at 4OC (220V, 20 mA).  
The gel was stained with coomassie blue to confirm that the protein has been electroeluted and there was no 
MMP-3 band left. The electroeluted protein was then precipitated in cold absolute ethanol and the pellet was 
collected. The MMP-3 pellet will then be used as immunogen for inducing MMP3 polyclonal antibody 
production. 
2.3. Immunisation and measurement of anti-MMP-3 polyclonal antibody in rabbits   
The 54 kDa MMP-3 protein (200 µL isolate protein in 200 mlCFA) that has been characterized from the 
participants was injected to 8 rabbits to generate anti-MMP-3 polyclonal antibody. The protocol of MMP-3 
immunization and harvest of MMP-3 antibody is showed in the below (Table 1). 
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Table 1:  MMP-3 immunisation and MMP-3 antibody harvest in rabbit 
Day Activity Treatment 
0 Bleeding (pre-treatment)  
1 First Immunisation 200µl MMP-3 isolate + 200 µLCFA 
(Complete Freund Adjuvant) 
28 Second Immunisation (booster 
1) 
200µl MMP-3 isolate + 200µL CFA 
38 Bleeding 1  
45 Bleeding 2  
52 Bleeding 3  
59 Bleeding 4  
66 Bleeding 5  
69 Third Immunisation (booster 2) 200µl MMP-3 isolate + 200µL CFA 
81 Bleeding 6  
88 Bleeding 7  
96 Bleeding 8  
103 Bleeding 9  
110 Bleeding 10  
 
Blood was collected and the serum level of polyclonal MMP-3 antibody was determined using indirect ELISA 
methods as previously described.  
Antigen (MMP-3) at a concentration of approximately 100 µg/ml in 100 µL Carbonate-Bicarbonate buffer 
(Coating buffer) was placed in eachmicroplateand incubated at  4º C for 24 h. They were then washed 4 times in 
PBS-T for 3 min each and blocked with 100 µL Blocking buffer and incubated at room temperature for 2 h. 
After washing 100 µL primary antibody (polyclonal anti-MMP-3 from rabbit) was added at a concentration of 
1:40 and incubated for 2 h at room temperature. After another washing 100 µL secondary antibody was added 
(Anti Rabbit IgGBiotin Labelled) at a concentration of 1/2500 and incubated for 2 h at room temperature. After 
washing 100 µL SA-HRP substrate was added and incubated for 30 min at room temperature in the dark. Once 
the control colour turned yellow the reaction was stopped by adding 100 µl 1M HCL (Stop Reaction). Titre was 
measured using ELISA reader at the wavelength of 450 nm. Negative control was without antigen. 
2.4. Characterisation of MMP-3 produced by rabbits using DOT BLOT and Western blot 
Dot blot is a method used to test the presence of an antigen. Protein to be tested was put on a membrane and 
measured semi quantitatively by colour intensity using Corel Photopaint 12 program. Briefly MMP-3 isolate (50 
µl) was placed on the membrane and incubated for 30 min, blocked with PBS Skim 1% for 1 h and washed with 
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PBS-T (3x3 min). Primary antibody was added (polyclonal anti-MMP-3 from rabbit) and incubated for 2 h on a 
shaker, washed and incubated in secondary antibody Anti Rabbit IgG Alkaline Phospatase (1:2500) for 1 h. The 
membrane was then washed in PBS-T (3x3 min) then incubated in Western Blue Substrate Solution for 30 min. 
The reaction was stopped with H2O and the presence of colour and its intensity was observed and compared. 
Serumwas electrophoresed using SDS-PAGE as previously explained. The bands that present on the gel were 
then characterised to determine the presence of MMP-3 using Western blot methods and polyclonal anti-MMP-3 
antibody as previously explained.   
2.5. Statistics 
The level of serum MMP-3 measured by indirect ELISA from RA patients and controls was compared using 
Mann Whitney test.  
3. Results 
3.1. Serum MMP-3 concentration obtained from participants 
MMP-3 concentration from serum obtained from all participants was measured as the average of two 
measurements using indirect ELISA methods, listed below on Table 2.  
Using Mann Whitney test significant increase was found in RA patients serum MMP-3 level compare to 
controls (p = 0.020). 
Table 2: Serum MMP-3 concentration from all participants 
Sample 
Absorbance 
1 Absorbance 2 Average Concentration (ppm) 
Control 1 0,386 0,402 0,394 4,000 
Control 2 0,403 0,405 0,404 5,667 
Control 3 0,396 0,414 0,405 5,833 
RA 1 0,485 0,478 0,482 18,583 
RA 2 0,478 0,486 0,482 15,917 
RA 3 0,48 0,451 0,466 18,667 
RA 4 0,496 0,52 0,508 23,000 
RA 5 0,495 0,489 0,492 20,333 
RA 6 0,496 0,486 0,491 20,167 
 
3.2. MMP-3 characterisation using Western blot 
MMP-3 from serum obtained from controls and RA patients was characterised by Western blot showing MMP-3 
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bands (54 kDa). These were then be eluted and isolated (Figure 1). 
 
Figure 1: MMP-3 bands (54 kDa) from serum obtained from controls and RA patients 
3.3. MMP-3 measurements in immunised rabbits  
The concentrations of MMP-3 from rabbits were measured after immunisation as shown on table 3. 
Table 3: MMP-3 concentration from rabbits after immunisation. 
Bleeding no.  
Absorbance  Concentration after 
dilution 20x (ppm) 
Concentration before 
dilution 20x (ppm) 1 2 Average  
0 0,374 0,377 0,3755 0,9167 18,33 
1 0,419 0,414 0,4165 7,75 155,00 
2 0,427 0,421 0,424 9 180,00 
3 0,440 0,444 0,442 12 240,00 
4 0,408 0,436 0,422 8,6667 173,33 
5 0,412 0,420 0,416 7,6667 153,33 
6 0,435 0,436 0,4355 10,9167 218,33 
7 0,444 0,446 0,445 12,5 250,00 
8 0,456 0,455 0,4555 14,25 285,00 
9 0,422 0,413 0,4175 7,9167 158,33 
10 0,403 0,411 0,407 6,1667 123,33 
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3.4. Characterisation using DOT BLOT 
DOT BLOT experiment showed that all post immunisation bleeding were positive against MMP-3 while pre 
immunisation bleeding was negative confirming that the antibody detected in all post immunisation bleeding 
was polyclonal anti-MMP-3 antibody (Figure 2).  
 
Figure 2: Dot blot experiment showed positive reaction from all bleeding 1 – 10 post immunisation and 
negative reaction from pre immunisation bleeding confirming the presence of polyclonal anti-MMP-3 antibody. 
3.5. Identification of serum rabbit polyclonal MMP-3 antibody using Western blot 
Identification of polyclonal anti-MMP-3 antibody from the rabbit serum using Western blot (Figure 3) showed 
that positive MMP-3 band of controls and RA patients were the same as using monoclonal anti-MMP-3 
antibody. It confirmed that this antibody was polyclonal anti-MMP-3 antibody.  
 
Figure 3: Western blot experiment showed positive bands in the gels that matched the molecular weight size of 
MMP-3 using monoclonal anti-MMP-3 antibody 
4. Discussion 
MMP-3 has been shown to cleave a series of ECM proteins and is considered as an important protease in the 
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progression of joint damage in RA patients [22, 23]. Previous studies have indicated the prime importance of 
elevated synovial MMP-3 in RA which is positively correlated with synovitis assessed by comprehensive 
histological and inflammatory cell analysis [16]. Serum MMP-3 was also shown to be significantly correlated 
with synovial MMP-3 and synovitis level and had the ability to distinguish high grade from low grade synovitis 
in RA [16]. Supporting previous studies in this study we showed the presence of significant elevation of serum 
MMP-3 by indirect ELISA in patients with active progressive RA in comparison to controls which has no RA 
using Mann Whitney test  (p = 0.020). The difference could potentially be greater as we used male controls 
which are supposed to have significantly higher level of baseline serum MMP-3 in comparison to females [17]. 
At least we have the confidence that despite using male controls we can show 4 fold increase in the level of 
serum MMP-3 from our female RA patients.  Such MMP-3 has molecular weight 54 kDa, which is the whole 
MMP-3. Up to date detection of MMP-3 levels is limited by the availability of commercial assays, which 
potentially have unknown variabilities. We believe that custom made antibody sourced from individuals with 
similar geographical and disease condition could eliminate some of those unknown variabilities. As far as we 
are aware MMP-3 antibody from human RA source was never been developed in Indonesia to date and this 
study is the first attempt to develop this antibody in that geographical area. It potentially will be able to be used 
to more specifically detect MMP-3 in RA patients from similar disease background, race and area. In this study 
we have successfully developed rabbit polyclonal anti-MMP-3 antibody from the RA patients that showed 
MMP-3 specificity by dot blot, Western blot and ELISA methods. Previous investigators have developed 
monoclonal active MMP-3 in mice and found its positive expression in cultured synovial membrane and human 
cartilage explant supernatant [15]. They also discovered that active MMP-3 expression was significantly 
decreased after anti-TNF-α treatment, which could indicate that active MMP-3 could be used as a predictor of 
the treatment efficiency at the level of anti-inflammatory effects. The levels of expression however did not 
correlate to or predict changes in disease activity scores. Furthermore, active MMP-3 significantly correlated 
with CRP and ESR levels, which indicated that active MMP-3 plays important role and responsible for 
inflammation. In other studies serum whole MMP-3 was found as an independent predictor of structural damage 
progression in patients with ankylosing spondylitis [24] but no correlation was found in in active MMP-3 
expression in RA in vitro cultured synovial membrane and human cartilage explant which indicate active MMP-
3 behaves different than the classical inflammatory markers [15]. Previous finding has reported the limitations 
in relation to the detection of active MMP-3 in human serum. Active MMP-3 is known to bind to carrier 
proteins like TIMP and α-2 macroglobulin which are abundant in biological fluid and shield them in the 
subunits [25-27]. This could result in the difficulties in identifying the real expression of active MMP-3 and 
skew the levels in serum towards lower levels. The expression of active MMP-3 was shown in cultured cells and 
its usefulness as RA disease marker in human is still not confirmed [15]. Many investigators have found the 
correlation between serum MMP-3 expression and the disease activity and progression in human RA which was 
also shown in this study [3, 6, 8, 16, 24, 28]. Based on this consideration we believe that whole MMP-3 is a 
better alternative for RA marker. We believe that this study supported previous findings about the importance of 
serum MMP-3 in RA and could potentially be used for diagnostic purposes. Moreover we also showed in this 
study the ability to produce polyclonal MMP-3 antibody from RA patients in rabbits which could be very 
beneficial for use for community with similar geographical areas and background. This paper has limitation 
where the number of samples was relatively small and all participants were recruited from the same hospital. 
International Journal of Sciences: Basic and Applied Research (IJSBAR)(2017) Volume 33, No  2, pp 108-119 
117 
 
Further studies using larger number of samples recruited from different hospitals and/or different cities/countries 
is recommended to determine whether the similar upregulation of MMP-3 expression in RA can be found. 
Furthermore the properties of MMP-3 antibody production obtained from RA sufferers different geographical 
sites can be compared to determine the differences/similarities of the antibody produced based on geographical 
location. Recommendation then can be made on the most suitable antibody that can be used to identify/diagnose 
RA disease in a particular group of RA sufferers. 
5. Conclusion 
In this study we found significant increase of serum MMP-3 in our group of RA patients. The production of 
anti-MMP-3 antibody from their serum will be beneficial for future diagnostic and prognostic purposes for 
patients from similar geographical area. Currently none of the MMP-3 antibodies which are available 
commercially were produced in the Asian countries which raised questions about their specificity for the local 
use. 
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